Santarus, Inc. (NASDAQ:SNTS): Marketed & Approved Products


Dallas, Texas 11/06/2013 (Financialstrend) – In Tuesday’s trading, the opening price of Santarus, Inc. (NASDAQ:SNTS)  shares was $24.34, which climbed to an intraday high of $24.54 and dipped to a close of $24.32. Approximately 1.49 million shares were traded on Tuesday while an average volume of 1.78 million shares were traded over a 30 day period. The 52-week low of Santarus, Inc. (NASDAQ:SNTS) shares is $8.47 and its 52-week high is $28.10. The company has a market capitalization of $1.61 billion.                                        

About the company

Santarus, Inc. (NASDAQ:SNTS)  was incorporated on 22 April 2002. It  is a specialty bio-pharmaceutical company that focuses on the acquisition, development and commercialization of various  products that address needs of patients who have been treated by physician-specialists. As of 31 December 2012, its marketed 7 approved products included Uceris, Zegerid, Glumetza, Cycloset, tablets and Fenoglide tablets. As of 31 December 2012, its investigational-drugs included Ruconest Rifamycin SV MMX &  SAN-300.

Marketed & Approved Products

Uceris extended-release tablets are available in 9mg tablets. These are locally long- acting corticosteroid and are an oral tablet formulation. This uses the multi-matrix system. Uceris is used for induction of remission in those patients who suffer from  active, mild- moderate ulcerative colitis. Zegerid capsules & powder that is used in oral suspension. It is  available in 20 mg & 40 mg dosage-strengths and is an immediate-release formulation of proton-pump inhibitor.

Other products

Zegerid is used for short-term treatment of active-duodenal ulcer, short term treatment of active-benign gastric ulcer, the treatment of gastroesophageal-reflux disease, maintaining the  healing of erosive-esophagitis &  reducing risk of upper-gastrointestinal, bleeding in critically-ill patients. Glumetza is available in 500mg and 1000mg tablets. It is an extended-release, once-daily, formulation of metformin. It incorporates drug-delivery technology. Glumetza is the adjunct to diet & exercise to improve glycemic-control in adult-patients suffering from type 2 diabetes.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.